Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients.

ABSTRACT: Several small molecule biomarkers have been reported in the literature for prediction and diagnosis of (pre)diabetes, its co-morbidities, and complications. Here, we report the development and validation of a novel, quantitative method for the determination of a selected panel of 34 metabolite biomarkers from human plasma. We selected a panel of metabolites indicative of various clinically-relevant pathogenic stages of diabetes. We combined these candidate biomarkers into a single ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method and optimized it, prioritizing simplicity of sample preparation and time needed for analysis, enabling high-throughput analysis in clinical laboratory settings. We validated the method in terms of limits of detection (LOD)

SUBMITTER: Ahonen L 

PROVIDER: S-EPMC6780060 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature